VIR BIOTECHNOLOGY INC · Data as of 2026-09-08
H2 2026
The Company expects to report updated dose-escalation data from its Phase 1 trial evaluating VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, as a monotherapy and in combination with pembrolizumab, in the second half of 2026.Source filing
Q4 2026
Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.Source filing
Q4 2026
◦ Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026.Source filing
Q1 2027
Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.Source filing
Q1 2027
◦ Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.Source filing